[Expert Consensus on the Treatment of Antiangiogenic Agents for Radiation Brain Necrosis].

Abstract

Vascular damage is followed by vascular endothelial growth factor (VEGF) expression at high levels, which is an important mechanism for cerebral radiation necrosis (CRN) development. Antiangiogenic agents (Bevacizumab) alleviates brain edema symptoms caused by CRN through inhibiting VEGF and acting on vascular tissue around the brain necrosis area. Many studies have confirmed that Bevacizumab effectively relieves symptoms caused by brain necrosis, improves patients' performance status and brain necrosis imaging. Considering that the efficacy of antiangiogenic therapy is mainly related to the duration of drug action, low-dose antiangiogenic agents can achieve favorable efficacy. Prevention is the best treatment. The occurrence of CRN is associated with tumor-related factors and treatment-related factors. By controlling these factors, CRN can be effectively prevented.
.

• Authors: Yi Chen, Xin Wang, Bing Sun, Maobin Meng, Enmin Wang, Zhiyong Yuan, Hongqing Zhuang, Society of Radiation Oncology, Chinese Medical Education Association
• Journal: Zhongguo fei ai za zhi = Chinese journal of lung cancer (Zhongguo Fei Ai Za Zhi) Vol. 25 Issue 5 Pg. 291-294 (May 20 2022) ISSN: 1999-6187 [Electronic] China
• PMID: 35570144 (Publication Type: Journal Article)

Chemical References

• Angiogenesis Inhibitors
• Vascular Endothelial Growth Factor A
• Bevacizumab

Topics

• Angiogenesis Inhibitors (pharmacology)
• Bevacizumab (pharmacology, therapeutic use)
• Brain (metabolism)
• Consensus
• Humans
• Lung Neoplasms (drug therapy)
• Necrosis (drug therapy, etiology)
• Radiation Injuries (drug therapy, etiology)
• Vascular Endothelial Growth Factor A (metabolism)